A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Trastuzumab deruxtecan
Related studies linked through entity extraction aliases.
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
- Status
- COMPLETED
- Phase
- PHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
- Status
- COMPLETED
- Phase
- PHASE3
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE1